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HER-2/neu gene ampliﬁcation and cell surface overexpression are important factors in breast cancer for prognosis and
prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. In lung cancer, the clinical signiﬁcance of HER-2/neu
expression is currently under evaluation. We investigated 238 non-small lung carcinomas for HER-2/neu protein
overexpression by immunohistochemistry using the HercepTest. We found 2+ or 3+ overexpression in 39 patients (16%),
including 35% in adenocarcinomas and 20% in large cell carcinomas, but only 1% of squamous cell carcinomas. Marked (3+)
overexpression was uncommon (4%). The association between protein expression and gene copy number per cell, as
determined by ﬂuorescence in situ hybridisation assay, was investigated in 51 of these NSCLC tumours. Twenty-seven
tumours (53%) were negative by both tests. Marked (3+) protein expression and gene ampliﬁcation were present in only 4%
of samples. In 11 tumours (21%), gene gain was accompanied by chromosomal aneusomy and did not result in high protein
levels while in 7 (14%) the score 2+ was associated with maximum number of signals per cell 59. The prognostic implication
of HER-2/neu protein expression was studied in 187 surgically resected tumours. No statistical difference in survival was
observed comparing patients with positive (2+/3+) and negative tumours (0/1+), although 3+ patients showed a tendency to
shorter survival. The therapeutic implications of protein expression and gene ampliﬁcation in lung cancer need to be examined
in prospective clinical trials.
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Lung cancer is the leading cause of cancer death in both men and
women in the US (Greenlee et al, 2001). A better understanding of
the biologic pathways that drive neoplastic cellular proliferation has
led to the development of targeted therapies aimed at speciﬁc
proteins in these pathways. Among these are trastuzumab (Hercep-
tin
R), a humanised monoclonal antibody that recognises the HER-
2/neu protein receptor. The human HER-2/neu oncogene is located
on chromosome 17 and encodes a transmembrane glycoprotein of
185 kD, which has intrinsic tyrosine kinase activity (Stern et al,
1986), and shares sequence homology with the epidermal growth
factor receptor (Coussens et al, 1985; Slamon and Clark, 1988).
HER-2/neu overexpression has been observed by various diag-
nostic modalities in 20–30% of human breast cancers and is
associated with a poorer overall survival and resistance to hormone
based therapy (Slamon et al, 1987, 1989; Berchuck et al, 1990; Liu
et al, 1992; Press et al, 1994; Pauletti et al, 1996; Allred and Swan-
son, 2000; Jacobs et al, 2000). Trastuzumab was approved by the
US Food and Drug Administration (FDA) for the treatment of
breast cancer patients whose tumours overexpress HER-2/neu.
Trastuzumab produced objective responses in 26% of previously
untreated breast cancer patients (Vogel et al, 2001) and 15% of
breast cancer patients in the second line setting (Cobleigh et al,
1999). Response rates were considerably higher when trastuzumab
was combined with doxorubicin or paclitaxel (45%), and breast
cancer patients treated with the combination had higher response
rates and longer survival than patients treated with doxorubicin
or paclitaxel alone (Slamon et al, 2001).
Several studies evaluated HER-2/neu oncogene and protein
expression in lung cancers using immunohistochemical (IHC)
techniques (Schneider et al, 1989; Kern et al, 1990; Tateishi et al,
1991; Paakko et al, 1992; Tsai et al, 1993; Hsieh et al, 1998). These
studies reported overexpression of HER-2/neu in 27–57% of
patients with non-small cell lung carcinomas (NSCLC), with
adenocarcinomas having the highest rates of overexpression. This
wide variation in frequency is likely to be related to differences
in the methodologies tested and patient populations studied. The
overexpression of HER-2/neu in NSCLC has been associated with
a poorer survival and shortened time to relapse (Tateishi et al,
1991; Hsieh et al, 1998; Brabender et al, 2001; Korrapati et al,
2001) but these studies were limited by small sample sizes and
multivariate analysis was not performed. Additionally, in NSCLC
cell lines, overexpression of HER-2/neu has been reported to be
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www.bjcancer.comassociated with resistance to chemotherapeutic agents (Tsai et al,
1993) and a synergistic effect was obtained when trastuzumab
was combined with chemotherapeutic agents (Bunn et al, 2001).
The application of trastuzumab for the treatment of human lung
cancers that overexpress HER-2/neu is under investigation. In
breast cancer, a comparison between IHC and ﬂuorescence in situ
hybridisation (FISH) analyses showed FISH to be the method of
choice for predicting the clinical outcome (Pauletti et al, 2000).
The method of choice and the level of HER-2/neu protein expres-
sion required to obtain a potential therapeutic effect from
trastuzumab monoclonal antibody therapy has not yet been estab-
lished in lung cancer.
The purpose of this investigation was to characterise HER-2/neu
in primary lung cancers at protein and gene levels using the
HercepTest and DNA FISH probes. Furthermore, the prognostic
impact of the HER-2/neu protein expression was studied on a
series of 187 tissue microarrayed lung tumours.
MATERIALS AND METHODS
Comparison of immunohistochemistry (IHC) and
ﬂuorescence in situ hybridisation (FISH)
For the comparison of IHC and FISH, we studied 51 patients with
primary NSCLC treated at the University of Colorado and the
Veterans Administration Hospitals, Denver, CO. Sections of
tumour tissue were obtained by informed consent through the
Histopathology Core of the University of Colorado Cancer Center.
The tumour blocks were ﬁxed in 10% buffered formalin for 5–
10 h and embedded in parafﬁn. The blocks were cut in consecutive
4-micron sections. One section was stained with Hematoxylin and
Eosin (H&E), and classiﬁed according to the World Health Orga-
nisation (WHO) histologic classiﬁcation of lung tumours (Travis et
al, 1999). Areas rich in viable tumour cells were selected in the
H&E slides and subsequent sections were submitted for FISH
and HercepTest analyses in a blinded fashion.
The clinical characteristics of these patients were as follows:
There were 39 males and 12 females, and the median age was 65
years (range 46–79). According to the clinical stage, 15 patients
were classiﬁed in stage 1A, 17 in stage IB, four in stage IIA, four
in stage IIB and 11 in stage IIIA. Histologically, there were 24
adenocarcinomas, ﬁve large cell carcinomas (LCC), and 22 squa-
mous cell carcinomas (SCC). As positive controls, we used 12
pre-selected breast cancer specimens taken from the Histopatholo-
gic Core and known to be strongly positive (3+) by the HercepTest
method. In addition, 12 normal lung samples were selected from
autopsy material from patients without any history of neoplastic
or non-neoplastic pulmonary disease.
Immunohistochemistry (IHC) assay
The IHC procedure followed the DAKO’s protocol (DAKO
Corporation, Glostrup, Denmark) for the HercepTest. In brief,
the sections were deparafﬁnised, hydrated, and the antigen retrie-
val was performed at 958C in citrate buffer for 40 min. The
slides were then cooled at room temperature for 20 min, washed
with TRIS-buffer 363 min, and the peroxidase blocking was
performed for 5 min. After rewashing, the primary antibody
was applied for 30 min. Following the application of the second-
ary antibody the substrate–chromogen solution (DAB) was
added as a visualisation reagent. Finally the slides were counter-
stained with Hematoxylin.
Evaluation of the HercepTest followed the manufacturer’s
recommendation with a slight modiﬁcation. Each sample was
placed into one of four categories (0, 1+, 2+, 3+). Tumours with
complete absence of staining were scored as 0, those with weak,
incomplete membranous staining were classiﬁed as 1+. Tumours
with either strong, incomplete basolateral staining or weak,
complete membranous staining in greater than 10% of the tumour
cells were classiﬁed as 2+, and those with strong, complete
membranous staining in greater than 10% of the tumour cells were
classiﬁed as 3+. According to the HercepTest protocol, all tumours
classiﬁed as 2+ and 3+ were considered ‘positive’, and all tumours
scored as 0 or 1+ were classiﬁed as ‘negative’. Two observers (WA
Franklin and FR Hirsch) scored each slide, discrepancies were
discussed, and a consensus score provided.
Fluorescence in situ hybridisation (FISH) assay
Tissue sections were incubated at 658C for 4 h, deparafﬁnized in
three xylene washes for 10 min, and dehydrated in 100% ethanol.
After incubation in 26standard sodium citrate-SSC (pH 7.0) at
758C for 20–25 min, sections were digested with proteinase K
(0.25 mg ml
71 in 26SSC, pH 7.0) at 378C for 20–25 min, rinsed
in 26SSC (pH 7.0) at room temperature for 5 min, and dehy-
drated in ethanol series. Dual-target, dual-colour FISH assays
were performed using the PathVysion Her2 DNA probe kit (Vysis,
Downers Grove, IL, USA), including the LSI Her2 sequence
labelled in SpectrumOrange and the chromosome 17 centromere
sequence labelled in SpectrumGreen. The probe set was applied
to the selected area on each slide, the hybridisation area was
covered with a glass coverslip and sealed with rubber cement.
The slides were incubated at 808C for 10 min for co-denaturation
of chromosomal and probe DNA’s and hybridisation was allowed
to occur in a humidiﬁed chamber at 378C for 16–20 h. Post-
hybridisation washes were performed in 1.5 M urea/0.16SSC
(pH 7.0–7.5) at 458C for 30 min and in 26SSC for 2 min at
room temperature. After dehydration in an ethanol series, DAPI
(0.15 mg ml
71 in Vectashield Mounting Medium) was applied
for chromatin counterstaining. Each FISH assay included one or
two normal lung sections used as negative control, one or two
sections from breast adenocarcinomas previously identiﬁed as
carrying HER2 ampliﬁcation used as positive control and ﬁve or
six sections of lung carcinomas.
Microscopic analysis was performed on an Olympus BX60
brightﬁeld and epiﬂuorescence microscope equipped with the
Quips XL genetic workstation (Applied Imaging, Santa Clara,
CA, USA). Fluorescence signals were scored using single-band
ﬁlters for DAPI, FITC, and Texas red, a double-band pass ﬁlter
(FITC and Texas red) and a triple-band pass ﬁlter (DAPI, FITC
and Texas red, Chroma Technology, Brattleboro, VT, USA). Repre-
sentative images of each specimen were acquired with a SenSys
cooled CCD camera (Photometrics, Tucson, AZ, USA) in mono-
chromatic layers which were subsequently merged by the
SmartCapture software (Vysis, Downers Grove, IL, USA).
The histological areas previously selected in the H&E-stained
sections were identiﬁed in the FISH-treated slides. At least 200
non-overlapping interphase nuclei per site were scored for both
HER-2/neu and chromosome 17 centromere signals, following
strict scoring guidelines and constant adjustment of microscope
focus since signals located at different focal planes. Two indepen-
dent observers (L Chen and M Varella-Garcia) performed
analysis in a blinded fashion. All requisite techniques involved were
previously validated and results of scoring were found to be repro-
ducible between the two independent operators.
Prognostic implication of HER2 protein expression
Anonymous primary tumour tissue samples from patients diag-
nosed with non-small cell lung cancer pathological stage
(pStage) I–III were obtained from the University of Colorado
Cancer Center (UCCC) and the Johns Hopkins Medical Institu-
tions (JHMI) from 1993 through 1999. The Colorado and the
JHMI Institutional Review Boards approved the study protocol.
A total of 187 patients with complete medical records were
followed by the UCCC and JHMI tumour registries for survival
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British Journal of Cancer (2002) 86(9), 1449–1456 ã 2002 Cancer Research UKtime and outcome, and had adequate formalin-ﬁxed, parafﬁn-
embedded tissue blocks available for tissue microarray (TMA)
construction. The study population included 111 males and 76
females with a median age of 65 years. Ninety-four per cent
of the patients underwent thoracotomy, in which lobectomy were
performed in the majority of cases. Surgical margins were posi-
tive for tumour involvement in 8%. Mediastinoscopy with lymph
node resection was performed in the 11 non-resectable patients.
The tumours were staged according to the International Union
Against Cancer (UICC) TNM classiﬁcation, and histologically
subtyped and graded according to the WHO guidelines (Travis
et al, 1999). Histopathologic examination revealed that 52% of
the patients had pStage I disease. There were 95 SCC, 73 adeno-
carcinomas, 10 bronchoalveolar carcinomas (BAC), and 15 LCC.
Of all tumours, 52% were poorly differentiated. Median follow-
up was 51 months (range 18–100). Demographic and clinical
data were collected retrospectively. None of the patients received
radiotherapy or chemotherapy prior to surgery. The IHC proce-
dure was the same as described above. All tumour and control
tissues were reviewed by two pathologists (R Veve and WA
Franklin).
Tissue microarray construction
H&E stained sections were selected for tumour viability. Each
slide was marked, and the point in the corresponding parafﬁn
block was sampled for TMA construction. The TMAs were
assembled using a tissue-arraying instrument (Beecher Instru-
ments, Silver Springs, MD, USA), consisting of thin-walled
stainless steel biopsy needles and stylets used to empty and trans-
fer the needle content from the donor to recipient block. The
assembly is held in an X–Y position guide that is manually
adjusted by micrometers. Brieﬂy, the instrument was used to
create holes in a recipient parafﬁn block and to acquire tissue
cores from the donor block by a thin-walled needle. The cylind-
rical sample was retrieved from the selected region in the donor
block and extruded directly into the recipient block with deﬁned
array coordinates. A solid stylet, closely ﬁt in the needle, was
used to transfer the tissue cores into the recipient block. Taking
tumour heterogeneity into account, we used a large diameter
stylet (1.5 mm) and the study specimens were routinely over-
sampled with three replicate core samples of tumour (different
areas of the tumour) and normal (one, if present) regions, from
each donor block. Normal lung and 15 other control specimens
were included in each of the tissue array blocks. Multiple 4 mM
sections were cut with a Leitz microtome. Sections were trans-
ferred to adhesive coated slides using the adhesive-coated tape
sectioning system (Instrumedics, Hackensack, NJ, USA) as
described by Mucci et al (2000). Subsequently, UV light treat-
ment of the slides for 60 s polymerised the adhesive coating
into a plastic layer and sealed the sections to the slides. The tape
was then removed in a TPC solvent (Instrumedics, Hackensack,
NJ, USA). The sections were then deparafﬁnized with standard
xylene and hydrated through graded alcohols into water. One
section from each tissue array block was H&E stained and cover-
slipped. The remaining sections were stored at room temperature
for IHC staining.
Statistical analysis
Spearman correlation coefﬁcient was used to examine the relation-
ship between the maximum and the average number of the HER-2/
neu gene per cell and the ratio gene/chromosome by histology. The
Mantel–Haenszel Chi-square test was applied to examine the
differences in linear trend of HercepTest score and HER-2/neu
copy number per cell across the histologic subtypes of lung cancer.
For the survival analysis, the Kaplan–Meier method was applied to
estimate the lung cancer-related survival for each category of
HercepTest score. The log-rank test was applied to examine the
association between survival and HercepTest score. All statistical
analyses were carried out with SAS software (SAS Institute, Cary,
NC, USA).
RESULTS
Altogether, 238 patients with various NSCLC histologies were
included in the analyses. Thirty-nine patients (16%) had positive
HercepTest score (2+/3+), but only nine patients (4%) had a
strong positive result (3+). The distribution of the results from
the HercepTest according to the histological types is shown in
Table 1. Among 95 patients with adenocarcinomas, 33 patients
(35%) had a HercepTest positive tumour, and four out of 20
LCC patients (20%) had a positive tumour. Among 113 SCC
patients, only one (1%) had a HercepTest positive tumour. Typical
staining patterns are illustrated in Figure 1.
Correlation between FISH and IHC
Tumours from 51 of the patients were evaluated by both IHC and
FISH techniques. The distribution of the IHC results in this subset
was not statistically different from the total set of 238 patients.
Strong positive staining (3+) was observed in 6% of tumours, a
positive 2+ result was found in 19%, and 75% of the tumours were
negative (0–1+). The highest rates of positive staining were found
among the adenocarcinomas (42%) and LCC (40%), while only
5% of the SCC were positive. The difference across histological
subtypes was statistically signiﬁcant (P50.05, Mantel–Haenszel
Chi-square test for linear association).
In the FISH study each tumour was assessed by the average and
the maximum numbers of copies of the HER-2/neu gene per cell,
the average ratio of HER-2/neu gene to chromosome 17 copy
numbers, and the pattern of signal presentation (Tables 2 and 3,
Figure 2). There was a strong and signiﬁcant correlation between
maximum and average HER-2/neu copy numbers per cell (Spear-
man correlation coefﬁcient=0.93; P50.001). There was also a
signiﬁcant correlation between the maximum HER-2/neu copy
number and the ratio of HER-2/neu to chromosome 17 (Spearman
correlation coefﬁcient=0.54, P50.001).
The average number of HER-2/neu gene signals per cell was 2.9
and the average number of chromosome 17 signals was 2.6. The
average ratio gene/chromosome signals was 1.2. Of these 51
NSCLCs, only two (4%) had a maximum of 416 copies of the
HER-2/neu gene per cell (mean=ﬁve copies/cell) with a gene/chro-
mosome ratio 42, indicating true gene ampliﬁcation. The HER-2/
neu signals in these two tumours were presented in a clustered
pattern, consistent with that expected in homogenously staining
regions (Figure 2A,B). Fifteen cases (29%) had a maximum of
9–16 copies of the gene per cell (mean=three copies/cell). Small
clusters of signals were observed in seven of these 15 samples
(Figure 2C). In 26 cases (55%), the maximum number of copies
per cells was 5–8 (mean=2.6 copies/cell), and in eight cases
(16%) was 55 (mean=1.6 copes/cell). Except for the two tumours
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Table 1 Distribution of the immunohistochemistry scores (HercepTest)
according to the lung cancer histology in 238 non-small cell lung carcinomas
HercepTest scores
Positive
Histology 0 1+ 2+ 3+ Total (2+/3+)
Adenocarcinoma 54 8 26 7 95 35%
Large cell carcinoma 14 2 2 2 20 20%
Bronchoalveolar carcinoma 9 0 1 0 10 10%
Squamous cell carinoma 93 19 1 0 113 1%
Total NSCLC 170 29 30 9 238 16%
HER-2/neu in lung cancer
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1449–1456with clustered ampliﬁcation, all other tumours had gene/chromo-
some ratios 41.5. Therefore, in the NSCLC tumours, increased
number of copies of HER-2/neu per cell were largely due to chro-
mosomal polysomy and both ﬂuorescent signals (red for the gene,
green for the chromosome 17) displayed a scattered pattern as illu-
strated in Figure 2D.
In the normal lung specimens used as negative controls, the
maximum number of copies of the HER-2/neu gene per cell
was three, the average was 1.8 and the average ratio gene to
chromosome was 1.0. In contrast, all of the 12 breast cancer
samples used as positive controls had a clustered HER-2/neu
gene ampliﬁcation. The maximum number of copies ranged
from 14 to 30 and averaged 21.0. The average number of
copies per cell was 6.6 and the average ratio of gene/chromo-
some was 2.5.
The HER-2/neu gene copy number per cell did not differ
signiﬁcantly among the NSCLC histologic subtypes (P40.05 in
the Mantel–Haenszel Chi-Square test), but the normal lung
samples were statistically different from the cancer samples.
The maximum number of copies of HER-2/neu per cell averaged
8.1 in adenocarcinomas, 8.8 in LCC, and 7.1 in SCC. The aver-
age copy number of HER-2/neu per cell was 2.8 in
adenocarcinomas, 3.4 in LCC, and 2.7 in SCC. As presented in
Table 3, both of the lung tumour samples with a maximum
number of HER-2/neu copies per cell 416 were adenocarcino-
mas (4%). Among the 15 lung cancer samples with a
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HER2/neu expression patterns in adenocarcinoma of lung
Lateral/apical, normal epithelium Basolateral staining (2+)
Near complete membrane (2+), moderately differentiated Complete membrane (3+), poorly differentiated
Figure 1 Typical staining patterns by immunohistochemistry (HercepTest, Dako, Denmark): Normal epithelium with apical/lateral staining, but no baso-
cellular staining (Upper left). Modiﬁed 2+with a strong basolateral staining seen in some adenocarcinomas, but without complete membrane staining (Upper
right). A moderate near complete membrane staining in more than 10% of the cells, considered as 2+(lower left). Complete strong membrane staining,
considered as 3+(lower right).
Table 2 Results of the ﬂuorescence in situ hybridisation (FISH) analysis accordingly to the histology in 51 non-small
cell lung cancer specimens
Histology No. tumours
Ave. chr. 17
(range)
Ave. Her2
(range)
Ave. Ratio Her2/
chr. 17 (range)
Ave. Maximum
Her2/cell (range)
Adenocarcinoma 24 2.2 (1.5–3.5) 2.8 (1.7–5.9) 1.2 (0.9–2.3) 8.1 (5–30)
Large cell carcinoma 5 2.8 (1.4–3.7) 3.4 (2.4–3.7) 1.3 (1.0–1.8) 8.8 (8–10)
Squamous cell carcinoma 22 2.6 (1.0–4.6) 2.7 (1.0–4.6) 1.1 (0.6–1.4) 7.1 (2–8)
Total 51 2.5 (1.0–4.6) 2.9 (1.0–5.9) 1.2 (0.9–2.3) 7.8 (2–30)
Breast control (+) 12 2.6 (2.4–2.8) 6.6 (5.5–7.2) 2.5 (2.2–2.8) 20.7 (14–30)
Lung control (7) 12 1.8 (1.7–1.8) 1.8 (1.8–1.9) 1.0 (1.0–1.0) 2.8 (2–3)
HER-2/neu in lung cancer
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British Journal of Cancer (2002) 86(9), 1449–1456 ã 2002 Cancer Research UKmaximum of 9–16 copies of HER-2/neu per cell, six were
adenocarcinomas, six were SCC and three were LCC. Among
the 34 tumours with a maximum 59 copies of HER-2/neu
per cell, there were 16 adenocarcinomas, 16 SCC, and two LCC.
Twenty-seven tumours (53%) with HercepTest score of 0/1+
and a maximum number of copies of HER-2/neu per cell from
59 were considered negative by both analyses. Six tumours
(12%) with HercepTest score 2+/3+ and the maximum number
of copies of HER-2/neu per cell 59 were considered positive by
both analyses. Discordant results were observed in 18 cases
(35%). In seven (14%), the HercepTest was 2+ and the maximum
number of copies of HER-2/neu per cell was 59; in the remaining
11 (21%) there was a maximum of 59 copies of HER-2/neu per
cell and the HercepTest score was 0 or 1+.
Prognostic impact of HER-2/neu protein expression
Altogether 187 patients with NSCLC were examined for prognosis
related to HER-2/neu expression. Thirty-four tumours (18%) were
positive by HercepTest (2+/3+), but only six (3%) were strongly
positive (3+). Among 91 SCC, 8 tumours (9%) were positive
and all of them had 2+ HercepTest score. In contrast, among the
96 tumours with non-squamous histologies, 26 (27%) had a posi-
tive HercepTest score, and six of them were 3+. Seventy-one
tumours were adenocarcinomas, from which 23 (32%) were posi-
tive and ﬁve (7%) were 3+.
Kaplan–Meier survival curves for the different groups are
presented in Figure 3. Based on the 187 patients, no difference
in survival was found comparing patients with positive
(HercepTest 2+/3+, n=34) and negative (HercepTest 0/1+,
n=153 pts) tumours (P=0.86). The 3-year/5-year survival was
70/58% for the HER-2/neu positive patients, and 66/60% for
the negative patients. When the 3+ patients were analysed sepa-
rately (n=6), the survival for these patients tended to be shorter
(3-year/5-year survival=50%). However, statistical analysis was
not performed due to the small number of patients. No differ-
ence in survival was observed for patients with squamous
histology comparing those with HER-2/neu positive (n=8) and
negative (n=83) tumours (P=0.60). Similarly, no difference in
survival was observed comparing patients with positive (n=26)
and negative (n=70) tumors in the non-squamous histology cate-
gories (P=0.91).
DISCUSSION
In the current study, we found HER-2/neu overexpression (2+ and
3+) by IHC in 16% of the NSCLC tumours, most frequently in
adenocarcinomas (35%) and LCC (20%). These results are similar
to most reports of NSCLC in the literature (Schneider et al, 1989;
Kern et al, 1990; Tateishi et al, 1991; Paakko et al, 1992; Tsai et al,
1993; Hsieh et al, 1998). Exceptions are some recent studies (Cox et
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Table 3 Comparison of FISH with histology and IHC results in 51
NSCLC patients
Max. HER-2/neu per cell
Parameter 0–4 5–8 9–16 416 Total
Histology
Adenocarcinoma 5 11 6 2 24
Large cell carcinoma 0 2 3 0 5
Squamous cell carcinoma 3 13 6 0 22
Total NSCLC 8 26 15 2 51
Breast Control (+) 0 0 3 9 12
Lung Control (7)1 2 0 0 0 1 2
HercepTest score
0 1 10 5 1 17
1+ 4 12 5 0 21
2+ 3 4 3 0 10
3+ 0 0 2 1 3
Figure 2 Dual-colour FISH assay using the PathVysion DNA probe (Vysis) in lung tissue sections. HER-2/neu probe is labelled in red (SpectrumOrange)
and chromosome 17 probe is labelled in green (SpectrumGreen). Chromatin in staining in blue (DAPI). Gene ampliﬁcation (Gene/Chromosome ratio
42.0) is illustrated in patients with adenocarcinomas with HercepTest score 0 in (A) and HercepTest score 3+ in (B). Small HER-2/neu clusters
(Gene/Chromosome ratio 1.2) are illustrated in (C) for a patient with squamous cell carcinoma and HercepTest 1+. Balanced aneusomy (Gene/Chromo-
some ratio 1.0) is shown in an adenocarcinoma patient with HercepTest score 2+ (D).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1449–1456al, 2001; Hirashima et al, 2001), in which lower frequencies of
NSCLC tumours with HER-2/neu overexpression were reported.
Discrepancies among the reported frequencies might be due to
different factors, including distribution of histological types, tissue
processing, criteria for the scoring and interpretation of the stain-
ing results.
No standard immunohistochemical protocol has been devel-
oped for lung cancer. The HercepTest was developed and
approved by the US FDA for evaluation of HER-2/neu in breast
cancer. Lung tumours are, however, morphologically more hetero-
geneous than malignant breast tumours, which increases the
difﬁculties in the interpretation of the HER-2/neu staining results.
We observed that a few lung adenocarcinomas (55%) had a
strong basolateral staining, but not a complete membrane stain-
ing. Because of the incomplete membrane staining, these
tumours might have been classiﬁed by others as ‘negative’, accord-
ing to the HercepTest. However, because of the strong intensity of
the staining pattern, we classiﬁed these tumours as having 2+
results (Figure 1). This could give a slightly higher frequency of
positive adenocarcinomas compared to other studies (Cox et al,
2001; Hirashima et al, 2001). However, the clinical signiﬁcance
of this scoring may not be relevant because 2+ tumours do not
have a worse prognosis and may not have a signiﬁcant beneﬁt
from HER-2/neu targeted therapy.
The HER-2/neu gene status has been scarcely investigated in
lung tumours. We evaluated the copy number of HER-2/neu
sequences per cell using a dual-colour FISH assay which included
the gene probe and the centromere probe as a control. There is
no uniform criterion to determine gene ampliﬁcation by FISH.
There is a general consensus that gene/chromosome ratio 42
represents gene ampliﬁcation, however, other parameters have also
been used. For instance, Pauletti et al (2000) found that the maxi-
mum number of copies of HER-2/neu in breast cancer cells
correlated with the worsening of the prognosis supporting that this
is a good index for assessing ampliﬁcation. In the current study, we
demonstrated that the maximum number of copies of HER-2/neu
per cell in lung tumours was positively correlated both with the
average number of HER-2/neu per cell and the gene/chromosome
ratio. Therefore, either one of these indices may be useful for
studying prognostic and therapeutical implications of the HER-2
overexpression.
When comparing IHC and FISH results, the HercepTest showed
positive results (2+/3+) in 25% of cases while the FISH showed
59 copies of the HER-2/neu gene per cell in 32% of cases but
516 copies of HER-2/neu per cell in only 4% of cases. Overall,
HER-2/neu overexpression was more common in adenocarcinomas
and LCC and less common in SCC both at the surface protein level
and at the gene level.
HER-2/neu gene ampliﬁcation, represented by the gene/chromo-
some ratio 42 was uncommon in the NSCLCs (two patients=4%)
and even when considering the adenocarcinomas, the fraction of
tumours with a maximum HER-2/neu copy number per cell
416 was 8%. Other studies, such as Hirashima et al (2001) and
Cox et al (2001) also detected clustered ampliﬁcation only in rare
cases of NSCLC. Disomic status for chromosome 17 was only
found in 16% of the NSCLC tumours included in our study. In
the majority of these tumours, there were increased numbers of
copies of HER-2/neu gene per cell accompanied by a balanced
chromosome gain (gene/chromosome ration *1). Since low levels
of HER-2/neu cell surface protein expression was the most
common ﬁnding in these tumours, the results support the conclu-
sion that the extensive chromosome 17 polysomy detected in lung
tumours is not associated with HER-2/neu protein overexpression.
Other detailed studies comparing the levels of HER-2/neu
protein expression by IHC with different levels of gene gain/ampli-
ﬁcation by FISH have not been published in lung tumours.
Comparing our results with the large series of breast tumours
reported by Pauletti et al (2000), a marked gene ampliﬁcation
and protein overexpression was considerably more common in
breast than in lung cancers (13% vs 4% for FISH results, 11% vs
6% for IHC results). Similarly, the complete lack of protein surface
expression (score 0) and gene copy numbers per cell 54 were also
more common in breast than in lung cancer (55% vs 15% for
FISH, 70% vs 36% for IHC). None of the lung cancers in our
series, including adenocarcinomas, had a maximum copy number
per cell 432 whereas 5% of the breast cancers have been reported
in this category (Pauletti et al, 2000). More often lung cancers had
marked chromosomal aneusomy, with a balanced increase in the
number of copies of chromosome 17 and HER-2/neu gene copies.
This balanced increase does not represent true gene ampliﬁcation
and its clinical implications remain to be determined.
There was a good correlation between the IHC and FISH results
in two-thirds of the tumours investigated. In the discrepant cases,
there were either increased aneusomy (no gene ampliﬁcation) with-
out increased levels in the protein expression or increased protein
expression without signiﬁcant increase in the number of copies of
the gene. Discrepancies between protein expression (IHC) and the
gene status (FISH) have also been reported in breast tumours
(Tubbs et al, 2001). Interestingly, one of our patients with true
gene ampliﬁcation by FISH had a negative score by IHC (Figure
2A). There are several potential reasons for these discrepant results
comparing IHC with FISH. The discrepancies might be due to
quality of ﬁxation and tissue processing, as well as disturbances
in the transcriptional or post-transcriptional controlling mechan-
isms.
The clinical relevance of gene ampliﬁcation or protein overex-
pression of HER-2/neu in HSCLC as detected by FISH and IHC
assays remains to be determined. Applying the HercepTest to a
tissue microarray of 187 surgically resected lung tumours, we could
not demonstrate any statistically signiﬁcant difference in prognosis
between patients with negative (0/1+) and with positive tumours
(2+/3+). A tendency of shorter survival was observed for patients
with 3+ tumours but no statistical analysis could be done due to
the small number of patients in this category.
Theoretically it might be predicted that the protein expression
would be superior for assessing response to trastuzumab therapy
because the antibody binds to the cell surface protein. In breast
cancer, however, FISH technique has been demonstrated to be a
more accurate and reliable method for selecting patients eligible
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Figure 3 Kaplan–Meier survival curves according to the results of
HercepTest.
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2000; Pauletti et al, 2000; Tubbs et al, 2001). In our previous
studies with lung cancer cell lines, we detected a positive correla-
tion between HER-2/neu expression by IHC and effectiveness of
treatment with trastuzumab alone or in combination with cyto-
static drugs (Bunn et al, 2001). In lung cancer patients, we
currently do not know which level of HER-2/neu protein expres-
sion or gene gain/ampliﬁcation will have prognostic/therapeutic
implications. These questions need to be addressed in prospective
trials. Based on the clinical experience from the breast cancer
studies, it might be of interest to focus on NSCLC patients with
3+ IHC results and/or those having tumours with gene ampliﬁca-
tion. Data from the current and other studies (Cox et al, 2001)
show that these conditions seem to be limited to adenocarcinomas
and LCC. Thus, the number of patients who might be candidates
for trastuzumab treatment seems to be more limited in the NSCLC
population than in the breast cancer population, and such prospec-
tive clinical trials in NSCLC will require multicenter studies.
However, taken the large amount of NSCLC patients into account,
still many patients might beneﬁt from such a treatment. Clinical
trials with trastuzumab in lung cancer should assess HER-2/neu
expression by both methods to determine which test is superior
for predicting response.
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